TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%

Reuters

05-14

<a href="https://laohu8.com/S/TXMD">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%

TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535848100"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535848100\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535848100?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535848100","market":"nz","top_or_hot":-1,"title":"TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TXMD\">TherapeuticsMD Inc.</a> Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TXMD","symbol_name":"TherapeuticsMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL17j2BT:1","article_id":"2535848100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535848100","pubTimestamp":1747166785,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TherapeuticsMD, Inc.  reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $ per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $ per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 mi","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TXMD":"TherapeuticsMD Inc."},"translate_title":"TherapeuticsMD Inc.报告2025年第一季度：净亏损收窄至63.6万美元，许可收入增长25.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TXMD":0.9},"content_text":"TherapeuticsMD Inc. Reports Q1 2025: Net Loss Narrows to $636K, License Revenue Increases 25.8%\n    \n\n        TherapeuticsMD, Inc. (NASDAQ: TXMD) reported its financial results for the first quarter ended March 31, 2025. The company disclosed a net loss from continuing operations of $636 thousand, or $(0.06) per basic and diluted common share, marking a decrease of $99 thousand compared to a net loss of $809 thousand, or $(0.07) per share, for the same period in 2024. License revenues from continuing operations, primarily derived from the Mayne License Agreement, increased by 25.8% to $393 thousand, up from $313 thousand in the first quarter of 2024. This increase was mainly due to changes in sales of licensed products. Total operating expenses also decreased by 13.1% to $1,264 thousand, attributed to efficiencies gained as a royalty-based business. Additionally, TherapeuticsMD is exploring various strategic alternatives, including potential acquisitions, mergers, or asset sales, although no specific outcome or timeline has been established. As of March 31, 2025, the company's cash and cash equivalents stood at $5.7 million.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TherapeuticsMD Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250513022104) on May 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}